EMAIL THIS PAGE TO A FRIEND

The Journal of neuroscience : the official journal of the Society for Neuroscience

Oligodendroglial maturation is dependent on intracellular protein shuttling.


PMID 25609610

Abstract

Multiple sclerosis is an autoimmune disease of the CNS resulting in degeneration of myelin sheaths and loss of oligodendrocytes, which means that protection and electrical insulation of axons and rapid signal propagation are impaired, leading to axonal damage and permanent disabilities. Partial replacement of lost oligodendrocytes and remyelination can occur as a result of activation and recruitment of resident oligodendroglial precursor cells. However, the overall remyelination capacity remains inefficient because precursor cells often fail to generate new oligodendrocytes. Increasing evidence points to the existence of several molecular inhibitors that act on these cells and interfere with their cellular maturation. The p57kip2 gene encodes one such potent inhibitor of oligodendroglial differentiation and this study sheds light on the underlying mode of action. We found that subcellular distribution of the p57kip2 protein changed during differentiation of rat, mouse, and human oligodendroglial cells both in vivo and in vitro. Nuclear export of p57kip2 was correlated with promoted myelin expression, higher morphological phenotypes, and enhanced myelination in vitro. In contrast, nuclear accumulation of p57kip2 resulted in blocked oligodendroglial differentiation. Experimental evidence suggests that the inhibitory role of p57kip2 depends on specific interactions with binding proteins such as LIMK-1, CDK2, Mash1, and Hes5 either by controlling their site of action or their activity. Because functional restoration in demyelinating diseases critically depends on the successful generation of oligodendroglial cells, a therapeutic need that is currently unmet, the regulatory mechanism described here might be of particular interest for identifying suitable drug targets and devising novel therapeutic approaches.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

32883
4-tert-Octylphenol monoethoxylate solution, 1 μg/mL in acetone, analytical standard
C16H26O2
32882
4-tert-Octylphenol monoethoxylate solution, 10 μg/mL in acetone, analytical standard
C16H26O2
1009005
Acetylcysteine, United States Pharmacopeia (USP) Reference Standard
C5H9NO3S
A0150000
Acetylcysteine, European Pharmacopoeia (EP) Reference Standard
C5H9NO3S
MAB342
Anti-Galactocerebroside Antibody, clone mGalC, 50 µg, Anti-Galactocerebroside Antibody, clone mGalC is an antibody against Galactocerebroside for use in ELISA, IC, IH & WB.
MAB5680
Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibody, 100 µg, Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibody is an antibody against Myelin Oligodendrocyte Glycoprotein (MOG) for use in FC, IC, IH & WB.
P0357 Anti-p57Kip2 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
A7250
N-Acetyl-L-cysteine, Sigma Grade, ≥99% (TLC), powder
C5H9NO3S
PHR1098
N-Acetyl-L-cysteine, Pharmaceutical Secondary Standard; Certified Reference Material
C5H9NO3S
A5099
N-Acetyl-L-cysteine, PharmaGrade, Ajinomoto, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture
C5H9NO3S
A8199
N-Acetyl-L-cysteine, BioXtra, ≥99% (TLC)
C5H9NO3S
A9165
N-Acetyl-L-cysteine, cell culture tested, BioReagent
C5H9NO3S